IDEAYA Biosciences, Inc. Shareholders' Equity
IDEAYA Biosciences, Inc. (IDYA) had Shareholders' Equity of $1.20 billion as of 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:StockholdersEquity · last filed 2026-08-04
- 2026-06-30: Stockholders' Equity Attributable to Parent $1.20B.
- 2026-03-31: Stockholders' Equity Attributable to Parent $937.27M.
- 2025-12-31: Stockholders' Equity Attributable to Parent $1.02B.
- 2025-09-30: Stockholders' Equity Attributable to Parent $1.09B.
| Period end | Stockholders' Equity Attributable to Parent | Stockholders' Equity Attributable to Parent as first filed |
|---|---|---|
| 2026-06-30 | $1.20B 10-Q · filed 2026-08-04 | |
| 2026-03-31 | $937.27M 10-Q · filed 2026-08-04 | |
| 2025-12-31 | $1.02B 10-Q · filed 2026-08-04 | |
| 2025-09-30 | $1.09B 10-Q · filed 2025-11-04 | |
| 2025-06-30 | $959.65M 10-Q · filed 2026-08-04 | |
| 2025-03-31 | $1.02B 10-Q · filed 2026-08-04 | |
| 2024-12-31 | $1.06B 10-Q · filed 2026-08-04 | |
| 2024-09-30 | $1.18B 10-Q · filed 2025-11-04 | |
| 2024-06-30 | $931.66M 10-Q · filed 2025-11-04 | |
| 2024-03-31 | $935.31M 10-Q · filed 2025-08-05 | |
| 2023-12-31 | $621.09M 10-K · filed 2026-02-17 | |
| 2023-09-30 | $508.05M 10-Q · filed 2024-11-04 | |
| 2023-06-30 | $501.61M 10-Q · filed 2024-11-04 | |
| 2023-03-31 | $333.81M 10-Q · filed 2024-08-06 | |
| 2022-12-31 | $349.45M 10-K · filed 2026-02-17 | |
| 2022-09-30 | $368.77M 10-Q · filed 2023-11-07 | |
| 2022-06-30 | $269.32M 10-Q · filed 2023-11-07 | |
| 2022-03-31 | $288.67M 10-Q · filed 2023-08-10 | |
| 2021-12-31 | $301.51M 10-K · filed 2025-02-18 | |
| 2021-09-30 | $317.63M 10-Q · filed 2022-11-08 | |
| 2021-06-30 | $240.26M 10-Q · filed 2022-11-08 | |
| 2021-03-31 | $233.13M 10-Q · filed 2022-08-15 | $233.13M 10-Q · filed 2021-05-10 |
| 2020-12-31 | $198.27M 10-K · filed 2024-02-20 | |
| 2020-09-30 | $195.43M 10-Q · filed 2021-11-15 | |
| 2020-06-30 | $172.06M 10-Q · filed 2021-11-15 | |
| 2020-03-31 | $89.10M 10-Q · filed 2021-08-10 | |
| 2019-12-31 | $100.40M 10-K · filed 2023-03-07 | |
| 2019-09-30 | $110.41M 10-Q · filed 2020-11-12 | |
| 2019-06-30 | $120.61M 10-Q · filed 2020-11-12 | |
| 2019-03-31 | -$58.06M 10-Q · filed 2020-08-12 | |
| 2018-12-31 | -$48.95M 10-K · filed 2022-03-18 | |
| 2018-09-30 | -$40.74M 10-Q · filed 2019-11-13 | |
| 2018-06-30 | -$28.05M 10-Q · filed 2019-11-13 | |
| 2018-03-31 | -$21.31M 10-Q · filed 2019-08-12 | |
| 2017-12-31 | -$15.74M 10-K · filed 2021-03-23 | |
| 2016-12-31 | -$4.13M 10-K · filed 2020-03-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 | |
| Arcus Biosciences, Inc. (RCUS) | United States | $3.188B | -8.52 |
| Dyne Therapeutics, Inc. (DYN) | United States | $3.084B | -7.09 |
| Tango Therapeutics, Inc. (TNGX) | United States | $4.154B | -42.53 |